Cabozantinib (XL184) inhibits growth of prostate cancer in the bone and results in an altered bone environment

被引：0
|
作者：
Nguyen, Holly M. [1 ]
Brown, Lisha G. [1 ]
Gross, Ted S. [1 ]
Vessella, Robert L. [1 ]
Schimmiller, Frauke [2 ]
Corey, Eva [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Exelixis Inc, San Francisco, CA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-849
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
849
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cabozantinib (XL184) inhibits prostate tumor growth and bone lesion development
    Dai, Jinlu
    Zhang, Honglai
    Karatsinides, Andreas
    Aftab, Dana
    Schimmoller, Frauke
    Keller, Evan T.
    CANCER RESEARCH, 2012, 72
  • [2] Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models
    Sameni, Mansoureh
    Tovar, Elizabeth A.
    Essenburg, Curt J.
    Chalasani, Anita
    Linklater, Erik S.
    Borgman, Andrew
    Cherba, David M.
    Anbalagan, Arulselvi
    Winn, Mary E.
    Graveel, Carrie R.
    Sloane, Bonnie F.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 923 - 934
  • [3] Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).
    Apolo, Andrea Borghese
    Lee, Young H.
    Cecchi, Fabiola
    Agarwal, Piyush K.
    Parnes, Howard L.
    Khadar, Kattie
    Summerell, Amelia
    Gulley, James L.
    Compton, Kathryn
    Figg, William Douglas
    Dahut, William L.
    Bottaro, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC)
    Apolo, Andrea Borghese
    Lee, Young H.
    Cecchi, Fabiola
    Agarwal, Piyush K.
    Parnes, Howard L.
    Khadar, Kattie
    Summerell, Amelia
    Gulley, James L.
    Compton, Kathryn
    Figg, William Douglas
    Dahut, William L.
    Bottaro, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [5] A phase I study of cabozantinib (XL184) in patients with renal cell cancer
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. F.
    Morrissey, S.
    Ferguson, K. C.
    Holland, J.
    Kaelin, W. G.
    Dutcher, J. P.
    ANNALS OF ONCOLOGY, 2014, 25 (08) : 1603 - 1608
  • [6] A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
    Cabanillas, Maria E.
    Brose, Marcia S.
    Holland, Jaymes
    Ferguson, Kimberly C.
    Sherman, Steven I.
    THYROID, 2014, 24 (10) : 1508 - 1514
  • [7] Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial
    Tolaney, S. M.
    Nechushtan, H.
    Berger, R.
    Kurzrock, R.
    Ron, I. G.
    Schoffski, P.
    Awada, A.
    Yasenchak, C. A.
    Burris, H. A.
    Ramies, D. A.
    Shen, X.
    Winer, E. P.
    CANCER RESEARCH, 2011, 71
  • [8] A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
    Zhen, David Bing
    Griffith, Kent A.
    Ruch, Joshua Michael
    Morgan, Meredith
    Kim, Edward Jae-hoon
    Sahai, Vaibhav
    Simeone, Diane M.
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
    Viola, David
    Cappagli, Virginia
    Elisei, Rossella
    FUTURE ONCOLOGY, 2013, 9 (08) : 1083 - 1092
  • [10] Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
    Hussain, M.
    Smith, M. R.
    Sweeney, C.
    Corn, P. G.
    Elfiky, A.
    Gordon, M. S.
    Haas, N. B.
    Harzstark, A. L.
    Kurzrock, R.
    Lara, P.
    Lin, C.
    Sella, A.
    Small, E. J.
    Spira, A. I.
    Vaishampayan, U. N.
    Vogelzang, N. J.
    Scheffold, C.
    Ballinger, M. D.
    Schimmoller, F.
    Smith, D. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345